A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80 mg) Orally Administered Once Daily for 35 Days in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity. A Double Blind, Parallel Group, Placebo-controlled and Randomized Study.

Trial Profile

A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80 mg) Orally Administered Once Daily for 35 Days in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity. A Double Blind, Parallel Group, Placebo-controlled and Randomized Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 May 2013

At a glance

  • Drugs Elafibranor (Primary)
  • Indications Glucose intolerance; Metabolic syndrome; Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 May 2013 A combined analysis of four phase IIa studies was published in Hepatology, according to a GENFIT media release.
    • 04 Aug 2011 Results published in the Diabetes Care.
    • 17 Jan 2011 Actual initiation date (Jun 2009), lead trial investigators (Remy Hanf, Eric Bruckert) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top